Current HCV Treatment:  FDA approved medications to treat hepatitis C, side effect management, disease progression after successful treatment, and treatment of various populations of people with hepatitis C.

 

·        Disease Progression

o       361. Eradication of HCV Improves Hepatic Expression of Insulin Receptor Substrate 1/2 and Insulin Resistance.

o       M1867. Change of Serum Cholesterol Fractions In Patients With Chronic Hepatitis C After Sustained Viral Response To Ifn Therapy  

o       M1882. Does antiviral therapy affect liver cirrhosis progression?

o       S1240. Sustained virologic response to previous interferon treatment may reduce the risk for the recurrence of hepatocellular carcinoma in patients with hepatitis C  (updated, May 20)

o       S1728  The Prevalence and Significance of Occult Hepatitis B In A Liver Transplant population with Chronic Hepatitis C

 

·        General

o       362. Restoration Of Innate Immunity And Inhibition of Essential Host Factor For Replication Achieve Better Clinical Effect In Patients With Chronic Hepatitis C

o       M1005. Prevalence and clinical significance of hepatitis G virus coinfection in patients with chronic hepatitis C undergoing antiviral therapy.  (updated, May 28)  

o       M1800. Diabetes Mellitus is a Predictor of Treatment Failure in hepatitis C Patients Treated with Peg IFN and RBV (updated, May 24)

o       M1802. Post-treatment intrahepatic gene expression profiles associated with long-term virologic responses following peginterferon and ribavirin treatment for HCV genotype 1.

o       M1808. Metabolic Syndrome Is A Strong Predictor Of Treatment Failure In Patients With Chronic Hepatitis C (updated, May 21)

o       M1845. Retrospective Analysis of the Effect of Taking a Statin Along with Peginterferon and Ribavirin (PI+R) on SVR. (updated, May 22)

o       M1852. Role Of Hmg-Coa Reductase Therapy In Hepatitis C (HCV) Treatment Outcomes. (updated, May 21)

o       M1855. Predictive Value of a 12 Week Follow-up HCV RNA on SVR in Chronic HCV Patients Treated with Peg/RBV.

o       M1858. Cardiac stress test may not be indicated in patients with cardiac risk factors prior to antiviral therapy for chronic HCV. (updated, May 22)

o       M1859. Does RVR Predict SVR in Patients with Chronic HCV Genotype 2/3 Treated with Peginterferon and Ribavirin?

o       M1860. Peripheral Blood Leukocyte Ifnar-2 Expression in Aging Patients with Chronic Hepatitis C and an Effect of Ifn Therapy  (updated, May 22)

o       M1864. Predictors of Treatment Among Patients With Chronic Hepatitis C Virus Infection. 

o       M1866. Antiviral Completion Rates and Sustained Viral Response in Hepatitis C Patients with- versus without- Pre-existing Major Depressive Disorder.

o       M1870. Satisfaction with the decision to defer treatment for chronic hepatitis C (CHCV) infection declines over time: results of a 2-year follow-up questionnaire survey.

o       M1872. Safety and Tolerability of Peginterferon α-2a/Ribavirin in HCV Patients Non-Tolerant or Nonresponsive to Peginterferon α-2b/Ribavirin. (updated, May 22)

o       M1875. Limitation of combination therapy of peginterferon and ribavirin for older patients with chronic hepatitis C

o       M1876. Clinical significance of positive hepatitis C virus (HCV) transcription-mediated amplification (TMA) following response to anti-viral therapy 

o       M1880. Determining Current Barriers to Clinical Assessment and Antiviral Treatment in a cohort of U.S. Veterans referred for HCV Evaluation. (updated, May 22)

o       S1231. Peginterferon Alfa 2a / Ribavirin Versus Peginterferon Alfa 2b / Ribavirin Combination Therapy In Chronic Hepatitis C Genotype 3

o       S1232. Efficacy of a 72-week course of treatment for previous relapsers to PEG/ribavirin therapy (updated, May 20)

o       S1233. Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: Importance of patient selection and treatment experience (updated, May 20)

o       W1150. Antiviral treatment in Crohn ’s patients with chronic hepatitis C is well tolerated and effective.

 

·        Pegasys

o       4. Increased SVR Rate with 48 Wks’ Treatment and Higher RBV Dose in HCV Genotype 2/3 Pts Without a Rapid Virologic Response (RVR) Treated with Peginterferon Alfa-2a (40KD) (PEGASYS®) Plus RBV (COPEGUS®) (updated, May 28)

o       441. Peginterferon Alfa-2a (40KD) Plus Ribavirin for 16 or 24 Wks in Pts With HCV Genotype 2/3 Infection and Advanced Fibrosis/Cirrhosis (updated, May 28)

o       444. Sustained Virologic Response (SVR) Resulting From Treatment with Peginterferon Alfa-2a (40KD) (PEGASYS®) Alone or in Combination with Ribavirin (COPEGUS®) is Durable and Constitutes a Cure: an Ongoing 5-year Follow-up. (updated, May 21)

o       M1846. Cost-effectiveness of Early Treatment of Chronic Hepatitis C With Peginterferon Alfa-2a (40KD) Plus Ribavirin Before Progression to Advanced Liver Disease.  (updated May 23)

o       M1849. Herbal and Milk Thistle Use in the HALT-C Trial of Advanced Chronic Hepatitis C. (updated May 23)

o       M1850. Differences between genotype 1 patients with SVR or relapse after treatment for chronic hepatitis C (CHC) with peginterferon alfa-2a (40kd) (PEG) and ribavirin (RBV). (updated May 24)

o       M1851. Analysis of early viral kinetics in chronic hepatitis c genotype 2 or 3 patients treated with peginterferon alpha-2a and ribavirin. 

o       M1854. Treatment Duration and Histological Response to Peginterferon Alfa-2a/Ribavirin. (updated May 24)

o       M1856. Treatment of chronic hepatitis C (CHC) with peginterferon alfa-2a (40kd) (PEG) and ribavirin (RBV) in patients older than 60 years  (updated May 24)

o       M1861. Efficacy and Safety of Peginterferon Alfa-2a/Ribavirin in Methadone Maintenance Patients: Randomized Comparison of Direct Observed Therapy and Self Administration  (updated May 23)

o       M1868. Effect of Ethnicity on Higher Sustained Virologic Response Rates in Pts Receiving Peginterferon alfa-2a (40KD) and Ribavirin for HCV Genotype 1 Infection. 

o       M1879. Efficacy and Safety of Peg IFN alfa-2a and Low Dose Ribavirin in ESRD Patients with Hepatitis C

o       W1013. Predictive factors of sustained virological response to peginterferon alpha-2a therapy in the patients with chronic hepatitis C despite the discontinuation of peginterferon alpha-2a therapy due to adverse events. 

 

·        Peg-Intron

o       M1881. Effect of Peginterferon α-2b and Ribavirin combined therapy on serum gastrin and progastrin levels in relation to Helicobacter pylori (Hp) infection in patients with chronic hepatitis C (CHC). 

 

·        Side effects

o       M1806. Do growth factors improve EVR in chronic HCV-genotype 1 patients treated with Peg-Intron and Ribavirin? 

o       M1862. Improvement in Adherence to Therapy, Adverse Events (AEs) and Quality of Life (QOL) in Patients with Chronic Hepatitis C Treated with Pegylated Interferon Plus RibaPak™ Compared with Pegylated Interferon Plus Ribavirin. (updated May 24)

o       M1863. Prevalence and Risk Factors of Thyroid Disease in Patients Treated For Hepatitis C Virus. (updated May 23)

o       M1871. Darbepoetin Alfa and Filgrastim for the Management of Anemia and Neutropenia in Chronic Hepatitis C (CH-C).

o       T1044. Eltrombopag Maintains Platelet Counts During Myelosuppressive Pegylated Interferon Alpha Treatment of Chronic Hepatitis C Virus Infection. (updated May 23)

 

o       Psychosocial

§        M1813. Genome-wide analysis for genes that mediate IFN-induced depression in HCV patients.